No. There is no FDA rule requiring replacement at 10 years, or at any fixed interval. What the FDA does say is that breast implants are not lifetime devices, that complication risk rises the longer they are in place, and that patients with silicone gel implants should have their first ultrasound or MRI at 5 to 6 years after surgery, then every 2 to 3 years.
The “ten years” figure is one of the most durable pieces of misinformation in aesthetics. It circulates on practice websites, in consultation rooms, and now in AI-generated answers, where it gets repeated as though it were a device specification. It is not. Below is what the FDA’s own guidance and approved labeling actually say, taken from the source documents rather than from anyone’s summary of them.
Where does the 10 year number come from?
Nowhere official. No approved breast implant carries a manufacturer-stated service life, and the FDA has never issued a replacement interval.
What does exist, and what the number was probably distorted from, is a line in the FDA’s patient decision checklist example: “As many as 20 percent of women who receive breast implants for augmentation have to have their implants removed within 8 to 10 years, but my implants may last for a shorter or longer time.”
Read that carefully. It describes a minority outcome across a window, and it ends by saying the individual result is unpredictable. Somewhere between that sentence and the consultation room, “as many as 20 percent within 8 to 10 years” became “everyone at 10 years.” The distortion inverts the statistic: roughly four in five augmentation patients still have their original implants at the 10 year mark.
What does the FDA actually require in the labeling?
On October 27, 2021, the FDA approved new labeling for every legally marketed breast implant in the United States, following recommendations it issued in September 2020. The labeling now includes a boxed warning, a patient decision checklist the physician must review and sign with the patient, updated rupture screening recommendations, a materials list, and a patient device card.
The boxed warning opens with this: implants are not considered lifetime devices, the longer people have them the greater the chance of complications, and some of those complications will require more surgery. It goes on to cover breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) and reported systemic symptoms.
Note what the warning does not contain. No date. No interval. No expiration. It describes a risk that accumulates with time, which is a different claim from a device that expires on a schedule.
What is the real screening schedule?
This is the part patients should be able to find, and mostly cannot.
| Implant type | First screening | Then | If symptoms or unclear results |
|---|---|---|---|
| Silicone gel-filled | Ultrasound or MRI at 5 to 6 years post-op | Every 2 to 3 years | MRI recommended |
| Saline-filled | None recommended | Not applicable | Rupture is visible without imaging |
That table is the FDA’s current recommendation, verbatim in substance. Saline implants get no screening schedule for a simple reason the FDA states in a footnote: when a saline implant ruptures, the saline leaks out and the implant visibly deflates, so imaging adds nothing.
Silicone is different. Most silicone ruptures are what the FDA calls silent ruptures, meaning the implant looks and feels unchanged and a physical exam will not catch it. MRI is the most effective detection method. In December 2023 the FDA added ultrasound as an acceptable alternative for screening patients without symptoms, which matters because ultrasound is cheaper and more widely available than MRI, and because insurance frequently covers neither.
The schedule changed once already. Before the 2020 guidance, the FDA recommended MRI beginning at 3 years and every other year after. Its General and Plastic Surgery Devices Advisory Panel, which met March 25 and 26 of 2019, reached consensus that the old schedule should be replaced with screening starting between years 5 and 6 and repeating every 2 to 3 years. A practice still telling patients “MRI at three years” is working from guidance that was superseded six years ago.
How often do patients actually need another operation?
More often than the marketing implies, and for reasons that have nothing to do with a calendar.
The FDA’s patient decision checklist lists long-term risk figures drawn from approved premarket approval applications, where each number is the highest percentage reported in any PMA through October 2019:
| Outcome | Reported in up to |
|---|---|
| Need for reoperation | 59.7% of patients |
| Capsular contracture | 51.7% of patients |
| Rupture or leaking | 31.2% of patients |
| Wrinkling of the implant | 20% of patients |
| Shifting of the implant | 11.5% of patients |
| Visibility of implant edges | 6% of patients |
These are ceilings, not averages, and they span the full study follow-up rather than a single year. They still make the point: reoperation is common, and it is driven by capsular contracture, rupture, dissatisfaction with size or shape, and personal preference. None of those arrive on an anniversary.
Demand for revision work is visible in the volume data too. The American Society of Plastic Surgeons 2025 Procedural Statistics Report, released September 2026, put reconstructive procedure growth at 6 percent year over year, led by hand reconstruction, scar revision and implant revision. Cosmetic surgical volume rose 7 percent, with breast augmentation among the three most requested procedures.
Why does this matter for a practice’s visibility?
Because “do implants need to be replaced every 10 years” is a question prospective patients type before they ever type a surgeon’s name, and the answer they get shapes the consultation they book.
Right now that answer usually comes from a content farm or an aggregator repeating the myth. When a practice publishes the actual schedule, sourced to the FDA, with the screening interval and the saline distinction stated plainly, it produces a page that answers the question better than the page currently ranking. That is the entire mechanism. There is no trick underneath it.
Three things make such a page work:
State the answer in the first two sentences. Retrieval systems and skim-readers both stop at the top of the page, and a page that buries the answer under 400 words of throat-clearing loses to one that does not.
Link to the primary document. The FDA guidance, the labeling page, the manufacturer’s own patient brochure. A number with a traceable source survives fact-checking; a number without one gets dropped.
Say what you do not know. “Your implants may last a shorter or longer time” is the FDA’s own framing, and repeating that honestly reads as more credible than a confident interval nobody can support.
One caution on the technical side, since it gets oversold. Adding FAQ schema markup to the page does not make AI assistants more likely to cite it. The only controlled test on record, Ahrefs’ study of 1,885 pages against matched controls, found no significant uplift from structured data and a negative association for AI Overviews. Schema is worth adding for rich-result eligibility and machine readability. It is not a citation lever, and any vendor selling it as one is guessing.
Frequently asked questions
Is there an expiration date on breast implants?
No. No FDA-approved breast implant carries a stated service life or expiration date. The FDA’s boxed warning says implants are not considered lifetime devices and that complication risk increases over time, which describes accumulating risk rather than a fixed endpoint.
When should I get my first implant screening?
If you have silicone gel implants and no symptoms, the FDA recommends your first ultrasound or MRI at 5 to 6 years after your surgery, then every 2 to 3 years after that. If you have symptoms at any point, or your ultrasound results are unclear, an MRI is recommended instead.
Do saline implants need MRI screening?
No. The FDA does not recommend rupture screening for saline-filled implants because a rupture is detectable without imaging. The saline leaks into the body and the implant loses its shape, which you or your surgeon will notice.
What percentage of women keep their original implants past 10 years?
The FDA’s patient decision checklist states that as many as 20 percent of augmentation patients have their implants removed within 8 to 10 years, which implies roughly 80 percent still have their originals at that point. The checklist adds that any individual’s implants may last a shorter or longer time.
Will insurance pay for implant screening or removal?
Often no. The FDA states directly that implant removal and replacement may not be covered even when there are complications, and even when the original surgery was covered, and that MRI or ultrasound screening may not be covered either. This is worth confirming with the carrier before surgery rather than after.
Does a rupture need to be fixed immediately?
A ruptured silicone implant should be evaluated by the surgeon, since gel can stay inside the scar capsule or migrate past it, and the FDA notes silicone that has migrated to distant tissue may not be fully removable. The urgency depends on findings, which is the case for having the imaging done on schedule rather than waiting for a symptom that silent ruptures do not produce.
The short version
There is no 10 year rule. There is a 5 to 6 year first screening for silicone, repeating every 2 to 3 years, no screening schedule for saline, and a boxed warning saying implants are not lifetime devices. Reoperation is common but is driven by capsular contracture, rupture and preference, not by a calendar. A practice that publishes those four facts with links to the FDA source documents has a better answer on the page than most of what currently ranks for the question.
Patients are asking this question somewhere other than your website. Claim your free AI visibility audit and see what the engines say about your practice today.
Tagged